Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportGeneral Clinical Specialties

Potassium iodide therapy may not impair efficacy of radioiodine therapy for Graves’ hyperthyroidism if discontinued 2 weeks before administration of I-131

MIka Tamura, Kunihiro Nakada, Katsuhiko Kato, Noriyoshi Kato, Tsunenori Mizukoshi and Sakurai Masayuki
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 508;
MIka Tamura
2Hokko memorial hospital Sapporo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kunihiro Nakada
3Hokko Memorial Hospital Sapporo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katsuhiko Kato
5Nagoya University Graduate School of Medicine Nagoya Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noriyoshi Kato
1H Sapporo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsunenori Mizukoshi
6Saiseikai Otal hospital Sapporo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sakurai Masayuki
4Hokko Memorial Hospital Sapppo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

508

Objectives: Use of potassium iodide (KI) has been gaining popularity as an adjunctive to anti-thyroid drugs (ATDs) for treating hyperthyroidism in countries where dietary iodine intake is sufficient. The aim of this study was to examine whether 2 weeks’ withdrawal of KI therapy was appropriate in patients who are planned to receive radioactive iodine I-131 therapy (RAI) for Graves’ hyperthyroidism (GH).

Methods: Commercially available KI pill in our country contains 38mg of iodine per pill. 41 patients with GH (M 7/F 34. Average of age 43.6yrs.), who had been pretreated by a combination of ATD and KI or KI alone underwent RAI. Thyroid weight (TW:g) was determined using US or CT. Dose of KI (mg/day) ranged from 50 to 300S (average:173). KI was withdrawn 14 days prior to RAI while ATDs were withdrawn 3 to 4 days prior to RAI. Patients were instructed to follow a low iodine diet from 7 days before to 3 days after administration of I-131. Dose of I-131 was adjusted so that more than 100Gy was delivered to the thyroid. Otherwise, 555 MBq of I-131 was administered. As a parameter for total body iodine, urinary iodine concentration normalized by urinary creatinine (UIC: μg/gCRE) was measured before withdrawal of KI (UIC1) and on the day of RIA (UIC2). Thyroid function and TRAb(IU/ml) were determined on the day of RIA. 24hr-radioiodine uptake (RU; %) was determined using a gamma camera and I-123. All patients were followed up for more than 1 year after RAI. Outcome of RAI was defined as successful when either of euthyroidism, subclinical hypothyroidism, or hypothyroidism was achieved within a year after RAI. Results of UIC, RU, and efficacy of RAI in patients (KI group) were compared with those in 54 patients with GH, who were pretreated ATD alone before RAI (ATD group).

Results: The average value of TW(g), TRAb (normal range:less than 2 (IU/L) and FT4 (normal range: 0.82-1.70ng/dL) on the day of RAI were 63, 16.2 and 3.9 , respectively. The average value of UIC2(μg/gCRE) in KI group was decreased to less than 0.1% of UIC1 (119.0 vs. 172449.7), but was higher than that in ATD group (119.0 vs.82.2, p=0.010). However, difference in RU was not significant between KI group and ATD group (66.5 vs. 62.0, p=0.127). Additionally, successful rate of RAI in KI group was comparable to that in ATD group (82 vs.85%, p=0.724, OR=0.807) among patients with a thyroid weight less than 90 g.

Conclusions: Pretreatment by KI does not impair therapeutic efficacy of RAI for GH if the drug is discontinued 2 weeks before administration of I-131 and is combined with low iodine diet for one week . Thus, pretreatment with KI may be feasible for patients with GH who are to undergo RAI.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Potassium iodide therapy may not impair efficacy of radioiodine therapy for Graves’ hyperthyroidism if discontinued 2 weeks before administration of I-131
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Potassium iodide therapy may not impair efficacy of radioiodine therapy for Graves’ hyperthyroidism if discontinued 2 weeks before administration of I-131
MIka Tamura, Kunihiro Nakada, Katsuhiko Kato, Noriyoshi Kato, Tsunenori Mizukoshi, Sakurai Masayuki
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 508;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Potassium iodide therapy may not impair efficacy of radioiodine therapy for Graves’ hyperthyroidism if discontinued 2 weeks before administration of I-131
MIka Tamura, Kunihiro Nakada, Katsuhiko Kato, Noriyoshi Kato, Tsunenori Mizukoshi, Sakurai Masayuki
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 508;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

General Clinical Specialties

  • Can FDG PET/CT imaging have a role in clinical cases of Dermatomyositis?
  • The Potential Role of NaF-PET/CT in Monitoring CAD Development in Patients with Moderate-to-Severe Psoriasis
  • COMMON PEDIATRIC NUCLEAR MEDICINE IMAGING STUDIES: A COMPREHENSIVE REVIEW
Show more General Clinical Specialties

Thyroid and Para-Thyroid

  • 18F-FCH PET/CT for patients with uremic hyperparathyroidism
  • Tc-99m DTPA orbital SPECT/CT guided Selection for riamcinolone Acetonide Injection in Patients with Thyroid Associated Ophthalmopathy
  • PET imaging of phosphodiesterase 4 in brain and peripheral organs of McCune-Albright syndrome
Show more Thyroid and Para-Thyroid

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire